These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25410306)

  • 1. Classification models of HCV NS3 protease inhibitors based on support vector machine (SVM).
    Wang M; Xuan S; Yan A; Yu C
    Comb Chem High Throughput Screen; 2015; 18(1):24-32. PubMed ID: 25410306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QSAR studies of the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by multiple linear regression (MLR) and support vector machine (SVM).
    Qin Z; Wang M; Yan A
    Bioorg Med Chem Lett; 2017 Jul; 27(13):2931-2938. PubMed ID: 28501513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.
    Pillaiyar T; Namasivayam V; Manickam M
    Curr Med Chem; 2016; 23(29):3404-3447. PubMed ID: 27160539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classification of HCV NS5B polymerase inhibitors using support vector machine.
    Wang M; Wang K; Yan A; Yu C
    Int J Mol Sci; 2012; 13(4):4033-4047. PubMed ID: 22605964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of HCV protease inhibitors.
    Chen KX; Njoroge FG
    Curr Opin Investig Drugs; 2009 Aug; 10(8):821-37. PubMed ID: 19649927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
    Lampa A; Ehrenberg AE; Gustafsson SS; Vema A; Kerblom E; Lindeberg G; Karlén A; Danielson UH; Sandström A
    Bioorg Med Chem; 2010 Jul; 18(14):5413-24. PubMed ID: 20541424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches.
    Ezat AA; Elshemey WM
    Life Sci; 2019 Jan; 217():176-184. PubMed ID: 30528183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of potential inhibitors for HCV NS3 genotype 4a by combining protein-ligand interaction fingerprint, 3D pharmacophore, docking, and dynamic simulation.
    El-Hasab MAE; El-Bastawissy EE; El-Moselhy TF
    J Biomol Struct Dyn; 2018 May; 36(7):1713-1727. PubMed ID: 28531373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.
    Belfrage AK; Abdurakhmanov E; Kerblom E; Brandt P; Oshalim A; Gising J; Skogh A; Neyts J; Danielson UH; Sandström A
    Bioorg Med Chem; 2016 Jun; 24(12):2603-20. PubMed ID: 27160057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational drug discovery: Ellagic acid as a potent dual-target inhibitor against hepatitis C virus genotype 3 (HCV G3) NS3 enzymes.
    Lim SK; Othman R; Yusof R; Heh CH
    Chem Biol Drug Des; 2021 Jan; 97(1):28-40. PubMed ID: 32657543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of non-macrocyclic small molecule inhibitors against the NS3/4A serine protease of hepatitis C virus through in silico screening.
    Chaudhuri R; Lee H; Truong L; Torres J; Patel K; Johnson ME
    J Chem Inf Model; 2012 Aug; 52(8):2245-56. PubMed ID: 22697413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance outside the substrate envelope: hepatitis C NS3/4A protease inhibitors.
    Özen A; Prachanronarong K; Matthew AN; Soumana DI; Schiffer CA
    Crit Rev Biochem Mol Biol; 2019 Feb; 54(1):11-26. PubMed ID: 30821513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrimination of Active and Weakly Active Human BACE1 Inhibitors Using Self-Organizing Map and Support Vector Machine.
    Li H; Wang M; Gong YN; Yan A
    Comb Chem High Throughput Screen; 2016; 19(6):470-80. PubMed ID: 27141991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing and molecular docking of cyclic peptides against HCV NS3 protease.
    Masoud MS; Bukhari SA; Qasim M; Naqvi SAR; Ashfaq UA
    Pak J Pharm Sci; 2017 Sep; 30(5(Supplementary)):1965-1969. PubMed ID: 29105629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships of HCV NS3 protease inhibitors evaluated on the drug-resistant variants A156T and D168V.
    Ortqvist P; Vema A; Ehrenberg AE; Dahl G; Rönn R; Akerblom E; Karlén A; Danielson UH; Sandström A
    Antivir Ther; 2010; 15(6):841-52. PubMed ID: 20834096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
    Wang AX; Chen J; Zhao Q; Sun LQ; Friborg J; Yu F; Hernandez D; Good AC; Klei HE; Rajamani R; Mosure K; Knipe JO; Li D; Zhu J; Levesque PC; McPhee F; Meanwell NA; Scola PM
    Bioorg Med Chem Lett; 2017 Feb; 27(3):590-596. PubMed ID: 28011221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of small molecule inhibitors against the NS3/4A serine protease of Hepatitis C virus genotype 3 via highthroughput virtual screening and in vitro evaluations.
    Sakhor W; Teoh TC; Yusof R; Lim SK; Razif MFM
    Trop Biomed; 2020 Sep; 37(3):609-625. PubMed ID: 33612776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus NS3/4a protease inhibitors.
    McCauley JA; Rudd MT
    Curr Opin Pharmacol; 2016 Oct; 30():84-92. PubMed ID: 27544488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative structure and bioactivity relationship study on HCV NS5B polymerase inhibitors.
    Wang M; Zhong M; Yan A; Li L; Yu C
    SAR QSAR Environ Res; 2014; 25(1):1-15. PubMed ID: 24283437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.